Johnson & Johnson backs Francis Medical’s prostate-cancer device and leads $100 million funding round for Delix Therapeutics

Johnson & Johnson has moved to deepen its bets on both cancer technology and mental health therapeutics, according to a report published Tuesday on Yahoo Finance. The company agreed to invest in Francis Medical, a move intended to help advance the firm’s Vanquish device for prostate cancer treatment, the report said.

Separately, Johnson & Johnson also led a $100 million funding round in Delix Therapeutics. The financing, described in the same report, is aimed at supporting Delix’s work in depression treatment, an area that has seen intense R&D activity in recent years as companies look for faster-acting or more durable options beyond existing therapies.

In Francis Medical’s case, J&J’s investment ties directly to a specific product platform rather than a broad research collaboration. The report frames the investment as support for advancing Vanquish, suggesting that Johnson & Johnson is looking to bring additional resources to a device-based approach in prostate cancer care.

Device-centered oncology efforts are often designed around improving precision, reducing side effects, or creating treatment pathways that can be deployed in more clinical settings. While the Yahoo Finance report does not lay out the technical mechanism or the stage of Vanquish’s development, it does indicate that Johnson & Johnson’s involvement is intended to accelerate progress for the prostate-cancer device.

For Delix Therapeutics, the $100 million round indicates continued appetite among large healthcare companies to fund early and mid-stage research in neuropsychiatry. Depression drug development typically faces high clinical hurdles, including demonstrating meaningful symptom improvements and tolerability across patient groups. The report does not specify Delix’s pipeline assets or trial status, but the size of the round indicates that investors are backing its strategy.

Johnson & Johnson’s dual-track approach reflects a broader pattern in the healthcare sector, where major firms look to balance near-term revenue drivers with longer-duration innovation bets. Investing in cancer technology can complement the company’s existing portfolio of pharmaceuticals and procedures, while funding depression research can extend its footprint in a different and challenging therapeutic category.

The report does not provide additional deal terms such as ownership stakes, governance rights, milestones tied to funding, or whether J&J’s investment includes manufacturing or commercial commitments. It also does not state whether the Francis Medical and Delix investments are part of a single corporate investment program or separate initiatives, nor does it disclose timing for expected regulatory or clinical milestones.

Investors and industry watchers will likely focus next on what Johnson & Johnson’s funding means for clinical development timelines. For Vanquish, questions include progress toward key study endpoints and how quickly device development and clinical validation can move through upcoming steps. For Delix, the near-term watch is whether the company provides more detail on its depression program, including which candidates are being funded and what trial readouts are planned.